Intermuscular adipose tissue and lean muscle mass assessed with MRI in people with chronic back pain in Germany: a retrospective observational study
- PMID: 40487774
- PMCID: PMC12141060
- DOI: 10.1016/j.lanepe.2025.101323
Intermuscular adipose tissue and lean muscle mass assessed with MRI in people with chronic back pain in Germany: a retrospective observational study
Abstract
Background: Chronic back pain (CBP) affects over 80 million people in Europe, contributing to substantial healthcare costs and disability. Understanding modifiable risk factors, such as muscle composition, may aid in prevention and treatment. This study investigates the association between lean muscle mass (LMM) and intermuscular adipose tissue (InterMAT) with CBP using noninvasive whole-body magnetic resonance imaging (MRI).
Methods: This cross-sectional analysis used whole-body MRI data from 30,868 participants in the German National Cohort (NAKO), collected between 1 May 2014 and 1 September 2019. CBP was defined as back pain persisting >3 months. LMM and InterMAT were quantified via MRI-based muscle segmentations using a validated deep learning model. Associations were analyzed using mixed logistic regression, adjusting for age, sex, diabetes, dyslipidemia, osteoporosis, osteoarthritis, physical activity, and study site.
Findings: Among 27,518 participants (n = 12,193/44.3% female, n = 14,605/55.7% male; median age 49 years IQR 41; 57), 21.8% (n = 6003; n = 2999/50.0% female, n = 3004/50% male; median age 53 years IQR 46; 60) reported CBP, compared to 78.2% (n = 21,515; n = 9194/42.7% female, n = 12,321/57.3% male; median age 48 years IQR 39; 56) who did not. CBP prevalence was highest in those with low (<500 MET min/week) or high (>5000 MET min/week) self-reported physical activity levels (24.6% (n = 10,892) and 22.0% (n = 3800), respectively) compared to moderate (500-5000 MET min/week) levels (19.4% (n = 12,826); p < 0.0001). Adjusted analyses revealed that a higher InterMAT (OR 1.22 per 2-unit Z-score; 95% CI 1.13-1.30; p < 0.0001) was associated with an increased likelihood of chronic back pain (CBP), whereas higher lean muscle mass (LMM) (OR 0.87 per 2-unit Z-score; 95% CI 0.79-0.95; p = 0.003) was associated with a reduced likelihood of CBP. Stratified analyses confirmed these associations persisted in individuals with osteoarthritis (OA-CBP LMM: 22.9 cm3/kg/m; InterMAT: 7.53% vs OA-No CBP LMM: 24.3 cm3/kg/m; InterMAT: 6.96% both p < 0.0001) and osteoporosis (OP-CBP LMM: 20.9 cm3/kg/m; InterMAT: 8.43% vs OP-No CBP LMM: 21.3 cm3/kg/m; InterMAT: 7.9% p = 0.16 and p = 0.0019). Higher pain intensity (Pain Intensity Numerical Rating Scale ≥4) correlated with lower LMM (2-unit Z-score deviation = OR, 0.63; 95% CI, 0.57-0.70; p < 0.0001) and higher InterMAT (2-unit Z-score deviation = OR, 1.22; 95% CI, 1.13-1.30; p < 0.0001), independent of physical activity, osteoporosis and osteoarthritis.
Interpretation: This large, population-based study highlights the associations of InterMAT and LMM with CBP. Given the limitations of the cross-sectional design, our findings can be seen as an impetus for further causal investigations within a broader, multidisciplinary framework to guide future research toward improved prevention and treatment.
Funding: The NAKO is funded by the Federal Ministry of Education and Research (BMBF) [project funding reference numbers: 01ER1301A/B/C, 01ER1511D, 01ER1801A/B/C/D and 01ER2301A/B/C], federal states of Germany and the Helmholtz Association, the participating universities and the institutes of the Leibniz Association.
Keywords: Body composition; Chronic back pain; German national cohort; Muscle composition; Physical activity.
© 2025 The Author(s).
Conflict of interest statement
SZ is a fellow in the TUM School of Medicine and Health Clinician Scientist. DT has received honoraria from Bayer, Germany, Philips, Germany, GE Healthcare. Furthermore, he holds shares in StratifAI GmbH, Germany, Synagen GmbH, Germany. JNK declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore, he holds shares in StratifAI GmbH, Germany, Synagen GmbH, Germany, and has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, Merck, MSD, BMS, Roche, Pfizer and Fresenius. JL received compensation for delivering an educational lecture at the Forum for Continuing Medical Education (FomF) and received honoraria from AstraZeneca and Novartis. She is a fellow in the TUM School of Medicine and Health Clinician Scientist and the DKTK School of Oncology and received travel grants by the DKTK, the Association for Molecular Pathology Europe Congress and was awarded Google's Gemma Academic Program. BW has received honoraria from Novartis and Philips and has received honoraria by the DFG, Dt. Krebshilfe, NIH, BMBF, BMWi. He holds shares in Need Inc. CLS has received honoraria from Siemens Healthineers and Bayer Healthcare and received research grants from BMBF/DLR and Siemens. TK has received a research grant from the German Federal Ministry for Education and Research (BMBF). LCA is a is an Albrecht-Struppler-Clinician Scientist Fellow, funded by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as by the Technical University of Munich–Institute for Advanced Study. She is a deputy editor for Radiology Advances. KB has received research grants from the European Union (101079894), Bayern Inovativ, German Federal Ministry of Education and Research, Else Kröner Foundation, Max Kade Foundation and Wilhelm-Sander Foundation and speaker fees from Canon Medical Systems Corporation and GE HealthCare. He is Advisor for the EU Horizon 2020 LifeChamps project (875329) and the EU IHI Project IMAGIO (101112053). TN, CM, AP, FBu, EC, FBa, MG, JSM, JW, TL, MH, MM, SHK, TP, AK, HH, MS and SR have no conflicts to declare.
Figures
References
LinkOut - more resources
Full Text Sources
Miscellaneous
